Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06431594 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

A Phase 1 study of Neoplasms and Solid Tumors, sponsored by GlaxoSmithKline.

Recruiting
Registry status
Phase 1
Development phase
385
Enrollment target
20
Study locations

NCT06431594 is a Phase 1 study of Neoplasms and Solid Tumors that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 385 participants, below the 1,619-participant average among 158 other Neoplasms trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06431594, a Phase 1 study of Neoplasms and Solid Tumors, is actively recruiting participants, sponsored by GlaxoSmithKline.

RECRUITING
Registry status
Phase 1
Development phase
385 participants
Enrollment target
20
Study locations

Study Summary

The goal of this study is to assess the safety and tolerability of GSK5733584. The study will also see how the levels of GSK5733584 change over time at different dose amount.

Conditions Studied

Neoplasms Solid Tumors

Interventions

  • DRUG GSK5733584

Study Locations (20)

Other

  • GSK Investigational Site - Cipoletti Rio Negro
  • GSK Investigational Site - Ciudad de Buenos Aires
  • GSK Investigational Site - Rosario
  • GSK Investigational Site - Leuven
  • GSK Investigational Site - Helsinki
  • GSK Investigational Site - Helsinki

Massachusetts

  • GSK Investigational Site - Boston
  • GSK Investigational Site - Boston

Michigan

  • GSK Investigational Site - Detroit
  • GSK Investigational Site - Grand Rapids

New South Wales

  • GSK Investigational Site - Blacktown
  • GSK Investigational Site - Macquarie University

Ontario

  • GSK Investigational Site - Ottawa
  • GSK Investigational Site - Toronto

Florida

  • GSK Investigational Site - Lake Mary

Kansas

  • GSK Investigational Site - Fairway

Tennessee

  • GSK Investigational Site - Nashville

Trial Details

FieldValue
Enrollment Target 385 participants
Start Date 2024-07-02
Est. Completion 2027-09-20
Phase Phase 1

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06431594

The ClinicalTrials.gov registry entry for NCT06431594 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 385 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,619-participant average among 158 other Neoplasms trials with a reported enrollment target (76% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which GSK5733584 is the first listed.

NCT06431594 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Massachusetts, Michigan.

Frequently Asked Questions

What is clinical trial NCT06431594 about?

NCT06431594 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors". The goal of this study is to assess the safety and tolerability of GSK5733584. The study will also see how the levels of GSK5733584 change over time at different dose amount.

What is the current status of trial NCT06431594?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 385 participants. The study started on 2024-07-02. Estimated completion is 2027-09-20.

What conditions does trial NCT06431594 study?

This clinical trial studies the following conditions: Neoplasms, Solid Tumors.

What interventions are being tested in trial NCT06431594?

The interventions under investigation include: GSK5733584 (DRUG).

Who is sponsoring clinical trial NCT06431594?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06431594 being conducted?

This trial has 20 study locations across Florida, Kansas, Massachusetts, Michigan, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasms

All registered trials for this condition

Solid Tumors

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.